Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, has granted an employment inducement award to a new employee. The award consists of an option to purchase 2,650 shares of company common stock at an exercise price of $17.50 per share, matching the closing price on Nasdaq Global Market on the grant date of March 3, 2025.
The option was issued under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and follows Nasdaq Listing Rule 5635(c)(4). The vesting schedule includes 25% vesting on March 3, 2026, followed by three equal annual installments, achieving full vesting by March 3, 2029. The option carries a ten-year term.
Cartesian Therapeutics (NASDAQ: RNAC), un'azienda biotecnologica in fase clinica focalizzata sulle terapie cellulari mRNA per le malattie autoimmuni, ha concesso un premio di assunzione a un nuovo dipendente. Il premio consiste in un'opzione per acquistare 2.650 azioni ordinarie della società a un prezzo di esercizio di $17,50 per azione, corrispondente al prezzo di chiusura sul Nasdaq Global Market alla data di concessione del 3 marzo 2025.
L'opzione è stata emessa nell'ambito del Piano di Incentivi per l'Assunzione Ampliato e Riformulato del 2018 della Società e segue la Regola di Quotazione Nasdaq 5635(c)(4). Il programma di maturazione prevede un vesting del 25% il 3 marzo 2026, seguito da tre rate annuali uguali, raggiungendo il pieno vesting entro il 3 marzo 2029. L'opzione ha una durata di dieci anni.
Cartesian Therapeutics (NASDAQ: RNAC), una empresa de biotecnología en etapa clínica centrada en terapias celulares de ARNm para enfermedades autoinmunitarias, ha otorgado un premio de inducimiento laboral a un nuevo empleado. El premio consiste en una opción para comprar 2,650 acciones ordinarias de la empresa a un precio de ejercicio de $17.50 por acción, coincidiendo con el precio de cierre en el Nasdaq Global Market en la fecha de concesión del 3 de marzo de 2025.
La opción se emitió bajo el Plan de Incentivos de Inducción Laboral Modificado y Reformulado de 2018 de la Compañía y sigue la Regla de Cotización Nasdaq 5635(c)(4). El cronograma de adquisición incluye un 25% de adquisición el 3 de marzo de 2026, seguido de tres cuotas anuales iguales, alcanzando la plena adquisición para el 3 de marzo de 2029. La opción tiene un plazo de diez años.
Cartesian Therapeutics (NASDAQ: RNAC)는 자가면역 질환을 위한 mRNA 세포 치료에 중점을 둔 임상 단계의 생명공학 회사로, 새로운 직원에게 고용 유인 보상을 부여했습니다. 이 보상은 2,650주의 회사 보통주를 $17.50의 행사 가격으로 구매할 수 있는 옵션으로 구성되어 있으며, 이는 2025년 3월 3일 부여일의 나스닥 글로벌 마켓 종가와 일치합니다.
이 옵션은 회사의 수정 및 재구성된 2018년 고용 유인 인센티브 보상 계획에 따라 발행되었으며, 나스닥 상장 규칙 5635(c)(4)를 따릅니다. 권리 행사 일정은 2026년 3월 3일에 25%가 행사되고, 이후 3회의 동일한 연간 할부가 이어져 2029년 3월 3일까지 전량 행사됩니다. 이 옵션은 10년의 유효기간을 가집니다.
Cartesian Therapeutics (NASDAQ: RNAC), une entreprise de biotechnologie en phase clinique axée sur les thérapies cellulaires à base d'ARNm pour les maladies auto-immunes, a accordé une prime d'incitation à un nouvel employé. Cette prime consiste en une option d'achat de 2 650 actions ordinaires de la société à un prix d'exercice de 17,50 $ par action, correspondant au prix de clôture sur le Nasdaq Global Market à la date d'attribution du 3 mars 2025.
L'option a été émise dans le cadre du Plan d'Attribution d'Incentives de Recrutement Modifié et Révisé de 2018 de la Société et suit la Règle de Cotation Nasdaq 5635(c)(4). Le calendrier de vesting comprend un vesting de 25 % le 3 mars 2026, suivi de trois versements annuels égaux, atteignant le vesting complet d'ici le 3 mars 2029. L'option a une durée de dix ans.
Cartesian Therapeutics (NASDAQ: RNAC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf mRNA-Zelltherapien für Autoimmunerkrankungen konzentriert, hat einem neuen Mitarbeiter eine Anreizvergütung gewährt. Die Vergütung besteht aus einer Option zum Kauf von 2.650 Aktien des Unternehmens zu einem Ausübungspreis von 17,50 $ pro Aktie, was dem Schlusskurs am Nasdaq Global Market am Vergabetag, dem 3. März 2025, entspricht.
Die Option wurde im Rahmen des geänderten und neu gefassten Anreizvergütungsplans für die Beschäftigung 2018 des Unternehmens ausgegeben und folgt der Nasdaq-Listing-Regel 5635(c)(4). Der Vesting-Zeitplan sieht eine Vesting von 25% am 3. März 2026 vor, gefolgt von drei gleichen jährlichen Raten, die bis zum 3. März 2029 zu einer vollständigen Vesting führen. Die Option hat eine Laufzeit von zehn Jahren.
- None.
- None.
FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to one new employee. On March 3, 2025, the Company issued to this employee an option to purchase 2,650 shares of the Company’s common stock with an exercise price of
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
What are the key terms of RNAC's new employee stock option grant?
When will the RNAC employee stock options fully vest?
What is the exercise price for RNAC's new employee stock options?
How long is the term of RNAC's newly granted employee stock options?
